It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Advance your glutamate receptor discovery with our validated NMDA platform. We provide purpose-built GluN1/2A, 2B, 2C and 2D receptor models that support high-throughput screening, automated electrophysiology, and pharmacological profiling.
We offer a suite of stable, purpose-built NMDA receptor assays to support hit discovery, lead optimization and SAR programs. Each assay format is designed for reproducible, high-resolution functional analysis. For tailored study designs, we can provide custom receptor co-expression, variant screening, and protocol flexibility to support gain or loss of function studies and novel target validation.
NDMA Receptor Assays
GluN1/2a
GluN1/2B
GluN1/2C
GluN1/2D
Functional Characterization
Our NMDA receptor platform enables detailed pharmacological profiling across all key receptor subtypes. Using high-throughput automated electrophysiology, we deliver sensitive, reproducible data that helps your quantify activity with confidence.
Flexible Assay Formats for Allosteric Selectivity
Our experienced bioscience team help clients’ projects progress through proof of concept in vivo studies and into the clinic by providing tailored biomarker solutions and human disease-relevant translational assays.
Data You Can Trust
95% assay success rate across replicates
Excellent data reproducibility across test runs
Flexible analysis options designed to answer questions that matter to you
Seamless integration into screening cascades and SAR workflows
Figure 1: Glutamate concentration-response curves for GluN1/2A-2D, recorded using automated patch clamp.
Figure 2: Subtype-selective inhibition of NMDA receptor subtypes by ifenprodil indicating specific NAM binding profiles.
GRIN variant screening using automated electrophysiology enables precise assessment of gain- and loss-of-function variants in…
Posters
Related Capabilities
We bring together a dynamic blend of new talent and experiences pharmaceutical industry experts from around the world, delivering excellence across each stage of discovery.
Comprehensive ion channel assays and bespoke cell lines deliver high-fidelity screening and safety insights, accelerating hit-to-lead and optimization.
Precise ion channel and transporter insights through tailored electrophysiology studies supporting target validation, hit identification, and lead optimization decisions.
Integrated hit identification using HTS, fragment screening, and advanced automation delivering high-quality starting points for successful drug discovery.
